Biopharmaceutical company Innovnet Biologics, Inc. announced today (9/3) that the National Medical Products Administration (NMPA) has approved SULINNO®, an adalimumab injection, for rheumatoid arthritis, ankylosing spondylitis and psoriasis treatment in China. Already widely used in North America and Europe, adalimumab injections are universally recognized for their safety and efficacy in treating various inflammatory diseases. The goal is to improve the quality of life of those in China suffering from rheumatoid arthritis, ankylosing spondylitis and psoriasis while maintaining accessibility and affordability.
Read more here.
More on: News Regulatory
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.